Investors & Media

Corporate Profile

Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases. As a leading orphan endocrine disease company, we create distinct and transformative treatments for a wide range of endocrine diseases where there is a significant unmet medical need. We are currently advancing a pipeline that includes the following potentially first-in-class product candidates:

  • Livoletide (AZP-531) for the treatment of Prader-Willi syndrome
  • Nevanimibe (ATR-101) for the treatment of classic congenital adrenal hyperplasia
  • MLE-301 for the treatment of vasomotor symptoms (VMS) associated with menopause

Corporate Presentation

January 2020 Investor Presentation

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

Upcoming Events

More events are coming soon.